NO20000860L - Cyclopeptide derivatives as adhesion inhibitors - Google Patents

Cyclopeptide derivatives as adhesion inhibitors

Info

Publication number
NO20000860L
NO20000860L NO20000860A NO20000860A NO20000860L NO 20000860 L NO20000860 L NO 20000860L NO 20000860 A NO20000860 A NO 20000860A NO 20000860 A NO20000860 A NO 20000860A NO 20000860 L NO20000860 L NO 20000860L
Authority
NO
Norway
Prior art keywords
adhesion inhibitors
cyclopeptide derivatives
cyclopeptide
derivatives
arteriosclerosis
Prior art date
Application number
NO20000860A
Other languages
Norwegian (no)
Other versions
NO20000860D0 (en
Inventor
Guenter Hoelzemann
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20000860D0 publication Critical patent/NO20000860D0/en
Publication of NO20000860L publication Critical patent/NO20000860L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelser med formel (I) hvor X, A, B og C har de i krav l angitte betydninger, samt deres salter, kan anvendes som integrininhibitorer, særlig til profylakse og behandling av sykdommer i blodomløpet, ved trombose, hjerteinfarkt, koronare hjertesykdommer, arteriosklerose, ved patologiske tilstander som underholdes eller propageres gjennom angiogenese og innen tumorterapien.Compounds of formula (I) wherein X, A, B and C have the meanings specified in claim 1, as well as their salts, can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory diseases, in thrombosis, heart attack, coronary heart disease, arteriosclerosis , in pathological conditions that are maintained or propagated through angiogenesis and within tumor therapy.

NO20000860A 1997-08-23 2000-02-22 Cyclopeptide derivatives as adhesion inhibitors NO20000860L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19736772A DE19736772A1 (en) 1997-08-23 1997-08-23 New guanidino-substituted bi:cyclic peptide compounds
PCT/EP1998/005161 WO1999010371A2 (en) 1997-08-23 1998-08-14 Cyclopeptide derivatives as adhesion inhibitors

Publications (2)

Publication Number Publication Date
NO20000860D0 NO20000860D0 (en) 2000-02-22
NO20000860L true NO20000860L (en) 2000-02-22

Family

ID=7839977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000860A NO20000860L (en) 1997-08-23 2000-02-22 Cyclopeptide derivatives as adhesion inhibitors

Country Status (18)

Country Link
EP (1) EP1007545A2 (en)
JP (1) JP2001514186A (en)
KR (1) KR20010022828A (en)
CN (1) CN1267306A (en)
AR (1) AR013650A1 (en)
AU (1) AU734829B2 (en)
BR (1) BR9811992A (en)
CA (1) CA2301182A1 (en)
DE (1) DE19736772A1 (en)
HU (1) HUP0003500A3 (en)
ID (1) ID23952A (en)
NO (1) NO20000860L (en)
PL (1) PL341090A1 (en)
RU (1) RU2200166C2 (en)
SK (1) SK2132000A3 (en)
TW (1) TW477793B (en)
WO (1) WO1999010371A2 (en)
ZA (1) ZA987558B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA43823C2 (en) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг PHARMACEUTICAL COMPOSITION FOR INTEGRIN INHIBITION <font face = "Symbol"> a </font> <sub> V </sub> <font face = "Symbol"> b </font> <sub> 3 </sub> cell adhesion mammal WAY treatment and prevention of diseases associated with cell adhesion DISORDERS, METHOD FOR BINDING LOCK integrin fibrinogen, a composition for wound healing
DE4310643A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
DE4415310A1 (en) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptides
JPH07316193A (en) * 1994-05-24 1995-12-05 Asahi Glass Co Ltd Peptide derivative and use thereof

Also Published As

Publication number Publication date
NO20000860D0 (en) 2000-02-22
TW477793B (en) 2002-03-01
RU2200166C2 (en) 2003-03-10
ID23952A (en) 2000-06-08
WO1999010371A2 (en) 1999-03-04
AU9531998A (en) 1999-03-16
SK2132000A3 (en) 2000-09-12
WO1999010371A3 (en) 1999-05-27
CA2301182A1 (en) 1999-03-04
EP1007545A2 (en) 2000-06-14
BR9811992A (en) 2000-09-05
CN1267306A (en) 2000-09-20
KR20010022828A (en) 2001-03-26
AR013650A1 (en) 2001-01-10
HUP0003500A3 (en) 2001-12-28
ZA987558B (en) 1999-02-23
PL341090A1 (en) 2001-03-26
DE19736772A1 (en) 1999-02-25
AU734829B2 (en) 2001-06-21
JP2001514186A (en) 2001-09-11
HUP0003500A2 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
NO20010203L (en) Diacylhydrazine derivatives as integrin inhibitors
TW372232B (en) Phenylalanine derivatives
NO991951L (en) Tienopyrimidines with phosphodiesterase V inhibitory effect
NO20000841L (en) N Aroylfenylalanin derivatives
CA2280727A1 (en) Bicyclic amino acids
ITTO950104A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
NO20021281D0 (en) Wash off investment composition
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
MY130661A (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias
CY1109191T1 (en) A NEW USE OF DIFFERIPRON
NO20002702L (en) thienopyrimidine
SE8304737D0 (en) carbostyril derivatives
NO983991L (en) Serine protease inhibitors
ITTO950099A0 (en) CATHETER, PARTICULARLY FOR THE TREATMENT OF CARDIAC ARHYTHMIAS.
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
WO2003059258A3 (en) Compositions and methods for treating heart failure
CA2348391A1 (en) Chromenone and chromanone derivatives as integrin inhibitors
NO20000016L (en) Cyclic azapeptides with angiogenic activity
BR9917495A (en) Derivatives of betulinic acid having antiangiogenic activity, processes to produce such derivatives and their use for the treatment of tumor-associated antiogenesis
WO2000048996A3 (en) β-ALANINE DERIVATIVES
WO2003059265A3 (en) Compositions and methods for treating heart failure
DE69533876D1 (en) Composition for the gene therapy of coronary artery disease.
TR200200278T2 (en) Calcilitic compositions
NO20000860L (en) Cyclopeptide derivatives as adhesion inhibitors